Effect of 10-Valent Pneumococcal Vaccine on Pneumonia among Children, Brazil
Eliane Terezinha Afonso, Ruth Minamisava, Ana Luiza Bierrenbach, Juan Jose Cortez Escalante, Airlane Pereira Alencar, Carla Magda Domingues, Otaliba Libanio Morais-Neto, Cristiana Maria Toscano, and Ana Lucia Andrade
Author affiliations: Federal University of Goiás, Goiania, Goiás, Brazil (E.T. Afonso, R. Minamisava, A.L. Bierrenbach, O.L. Morais-Neto, C.M. Toscano, A.L. Andrade); Pontifical Catholic University of Goiás, Goiania (E.T. Afonso); Ministry of Health, Brasilia, Brazil (J.J.C. Escalante, C.M. Domingues); University of Brasília, Brasília (C.M. Domingues); University of São Paulo, São Paulo, Brazil (A.P. Alencar)
Figure 3. . . Trends in rates of hospitalization for pneumonia (black) and for all respiratory causes (light gray) and all causes (dark gray) among children 2 months–2 years of age in 5 cities, Brazil, January 2005–August 2011. PCV10, 10-valent pneumococcal vaccine.
Page created: March 13, 2013
Page updated: March 13, 2013
Page reviewed: March 13, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.